AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
Go back to AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis| AbbVie (NYSE: ABBV) | Delayed: 233.87 +3.86 (1.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $230.01 | 52 Week High | $68.12 | |||
| Open | $232.97 | 52 Week Low | $50.71 | |||
| Day High | $234.95 | P/E | 50.73 | |||
| Day Low | $231.30 | EPS | $4.61 | |||
| Volume | 3,580,969 | |||||
| ENANTA PHARM (NASDAQ: ENTA) | Delayed: 13.73 +0.36 (2.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.37 | 52 Week High | $34.49 | |||
| Open | $13.22 | 52 Week Low | $20.39 | |||
| Day High | $14.12 | P/E | N/A | |||
| Day Low | $12.92 | EPS | $-3.18 | |||
| Volume | 280,632 | |||||
